Maze Therapeutics, Inc.
MAZE · XNASCIK 1842295fmd_0PRN2Y3XCV4N3WSPWJHRMWCHNNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 11 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Total revenues | 168 | – |
| Research and development | 83 | 108 |
| Total operating expenses | 110 | 143 |
| Operating income | 58 | (143) |
| Interest and investment income | 5 | 12 |
| Income before taxes | 53 | (131) |
| Income tax expense | 1 | 0 |
| Net income from continuing operations | 52 | (131) |
| Net income | 52 | (131) |
| Net income to common shareholders | 3 | (131) |